Lista de obras - William K. Oh - Dominio Público Uruguay

A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer

artículo científico publicado en 2004

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

artículo científico publicado en 2011

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer

artículo científico publicado en 2004

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

artículo científico publicado en 2008

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

artículo científico publicado en 2003

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

artículo científico publicado en 2008

A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients

artículo científico publicado en 2002

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

artículo científico publicado en 2006

A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study

artículo científico publicado en 2012

Absence of relationship between steroid hormone levels and prostate cancer tumor grade

artículo científico publicado en 2008

Accelerating precision medicine in metastatic prostate cancer

artículo científico publicado en 2020

Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone

artículo científico publicado en 2009

Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer

artículo científico publicado en 2009

Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer

article

Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis

artículo científico publicado en 2010

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.

artículo científico publicado en 2009

Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer

artículo científico publicado en 2006

Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis

artículo científico

Atypical metastases from prostate cancer: 10-year experience at a single institution

artículo científico

Bevacizumab treatment of prostate cancer

artículo científico publicado en 2012

CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers

scientific article published on 05 October 2008

Cabazitaxel

artículo científico publicado en 2010

Cancer therapy from bench to bedside

artículo científico publicado en 2010

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy

artículo científico publicado en 2010

Carboplatin for Stage I Seminoma

article

Castration-resistant prostate cancer: AUA Guideline

artículo científico

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

artículo científico publicado en 2006

Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes

artículo científico publicado en 2012

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

artículo científico publicado en 2011

Complementary and alternative therapies in prostate cancer.

artículo científico publicado en 2002

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.

artículo científico publicado en 2009

Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.

artículo científico publicado en 2009

Development of an integrated prostate cancer research information system.

artículo científico publicado en 2006

Dilemmas and controversies in the management of prostate cancer continue to present a vexing challenge to physicians and patients dealing with the disease. Preface

artículo científico publicado en 2010

Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy

artículo científico publicado en 2007

Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer

artículo científico publicado en 2008

Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?

artículo científico publicado en 2009

Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer.

artículo científico publicado en 2008

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer

article

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

artículo científico publicado en 2010

Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer

artículo científico publicado en 2005

Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients

artículo científico publicado en 2010

Emerging personalized approaches for the management of advanced urothelial carcinoma

artículo científico publicado en 2012

Evaluation of 8q24 and 17q risk loci and prostate cancer mortality

artículo científico publicado en 2009

Evaluation of the 8q24 prostate cancer risk locus and MYC expression.

artículo científico publicado en 2009

Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?

scientific article published on 01 May 2006

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up

artículo científico publicado en 2003

Functional enhancers at the gene-poor 8q24 cancer-linked locus.

artículo científico publicado en 2009

Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21.

artículo científico publicado en 2011

Genome-wide association study of prostate cancer mortality

artículo científico publicado en 2010

Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.

artículo científico publicado en 2011

High-risk localized prostate cancer: integrating chemotherapy

artículo científico publicado en 2005

Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase

scientific article published on 01 December 2007

Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR

scientific article published on 03 July 2018

Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer

artículo científico publicado en 2011

Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort

artículo científico publicado en 2010

Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer

artículo científico publicado en 2002

Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?

artículo científico publicado en 2007

Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update.

artículo científico publicado en 2003

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

artículo científico publicado en 2020

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

artículo científico publicado en 2017

Management of hormone refractory prostate cancer: current standards and future prospects

artículo científico publicado en 1998

Metabolic and toxicological considerations of newly approved prostate cancer drugs

artículo científico

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

artículo científico publicado en 2005

Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report

artículo científico publicado en 2001

Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity

artículo científico publicado en 2003

Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints.

artículo científico publicado en 2003

New paradigms in microtubule-mediated endocrine signaling in prostate cancer

artículo científico

Overcoming castration resistance in prostate cancer

artículo científico

Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results

artículo científico publicado en 2003

Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer

artículo científico publicado en 2002

PC-SPES and prostate cancer

scientific article published on 01 February 2002

PC3 is a cell line characteristic of prostatic small cell carcinoma.

artículo científico publicado en 2011

Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.

artículo científico publicado en 2011

Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer

article

Phase II study of sunitinib in men with advanced prostate cancer.

artículo científico publicado en 2009

Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer

artículo científico publicado en 2012

Photoluminescent polymer nanoparticles for label-free cellular imaging

artículo científico publicado en 2010

Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma

artículo científico publicado en 2003

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases

artículo científico publicado en 2007

Predicting outcome in localized prostate cancer: how far have we come?

artículo científico publicado en 2003

Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article

artículo científico publicado en 2010

Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy

artículo científico publicado en 2012

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

artículo científico publicado en 2009

Progressive sclerosis of isolated foot metastasis of prostate cancer

artículo científico publicado en 2002

Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.

artículo científico publicado en 2004

Prostate cancer risk associated loci in African Americans

scientific article published on 23 June 2009

Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study

artículo científico publicado en 2011

Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer

artículo científico publicado en 2004

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer

artículo científico publicado en 2006

Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases.

artículo científico publicado en 2002

Recent progress in hormonal therapy for advanced prostate cancer.

artículo científico publicado en 2006

Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.

artículo científico publicado en 2010

Relationship between serum adiponectin and prostate cancer grade.

artículo científico publicado en 2008

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer

artículo científico publicado en 2008

Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer

artículo científico publicado en 2006

Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes

artículo científico publicado en 2006

Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer

artículo científico publicado en 2007

Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-Based Chemotherapy

artículo científico publicado en 2011

Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.

artículo científico publicado en 2012

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

artículo científico publicado en 2004

SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer

artículo científico publicado en 2011

Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer

article

Secondary hormonal therapies in the treatment of prostate cancer.

artículo científico publicado en 2002

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma

artículo científico publicado en 2002

Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy

artículo científico publicado en 2010

Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.

artículo científico publicado en 2010

Sixty years of CA: a cancer journal for clinicians

artículo científico publicado en 2010

Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma.

artículo científico publicado en 2000

Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial

scientific article published on 20 April 2020

Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).

artículo científico publicado en 2012

The emerging role of circulating tumor cell detection in genitourinary cancer

artículo científico publicado en 2012

The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer.

artículo científico publicado en 2003

The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness

artículo científico publicado en 2011

The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels

artículo científico publicado en 2009

The medical management of prostate cancer: a multidisciplinary team approach.

artículo científico publicado en 2006

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.

artículo científico publicado en 2007

The role of ketoconazole in current prostate cancer care

article

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

artículo científico publicado en 2009

Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer

scientific article published on 01 November 2006

Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer.

artículo científico publicado en 2006

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

artículo científico publicado en 2011

Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis

artículo científico publicado en 2012

Trends in the use of cytoreductive nephrectomy in the United States

artículo científico publicado en 2012

Tumour angiogenesis: an elusive target in castration-resistant prostate cancer

artículo científico publicado en 2013

Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks

artículo científico publicado en 2012

Use of androgen deprivation therapy for metastatic prostate cancer in older men.

artículo científico publicado en 2008

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study

artículo científico publicado en 2000

What is the current status of second-line chemotherapy for castration-resistant prostate cancer?

scientific article published on 21 October 2008

Lista de obras de William K. Oh

A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study

Absence of relationship between steroid hormone levels and prostate cancer tumor grade

Accelerating precision medicine in metastatic prostate cancer

Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone

Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer

Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer

Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.

Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer

Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis

Atypical metastases from prostate cancer: 10-year experience at a single institution

Bevacizumab treatment of prostate cancer

CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers

Cabazitaxel

Cancer therapy from bench to bedside

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy

Carboplatin for Stage I Seminoma

Castration-resistant prostate cancer: AUA Guideline

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

Complementary and alternative therapies in prostate cancer.

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.

Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.

Development of an integrated prostate cancer research information system.

Dilemmas and controversies in the management of prostate cancer continue to present a vexing challenge to physicians and patients dealing with the disease. Preface

Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy

Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer

Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?

Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer.

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer

Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients

Emerging personalized approaches for the management of advanced urothelial carcinoma

Evaluation of 8q24 and 17q risk loci and prostate cancer mortality

Evaluation of the 8q24 prostate cancer risk locus and MYC expression.

Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up

Functional enhancers at the gene-poor 8q24 cancer-linked locus.

Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21.

Genome-wide association study of prostate cancer mortality

Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.

High-risk localized prostate cancer: integrating chemotherapy

Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase

Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR

Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer

Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort

Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer

Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?

Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update.

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Management of hormone refractory prostate cancer: current standards and future prospects

Metabolic and toxicological considerations of newly approved prostate cancer drugs

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report

Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity

Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints.

New paradigms in microtubule-mediated endocrine signaling in prostate cancer

Overcoming castration resistance in prostate cancer

Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results

Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer

PC-SPES and prostate cancer

PC3 is a cell line characteristic of prostatic small cell carcinoma.

Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.

Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer

Phase II study of sunitinib in men with advanced prostate cancer.

Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer

Photoluminescent polymer nanoparticles for label-free cellular imaging

Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma